PB1756: INOTUZUMAB OZOGAMICIN IN THERAPY RELAPSE/REFRACTORY B-CELL ACUTE LYMPHOBLASTIC LEUKEMIA (R/R B-ALL): A SINGLE CENTER EXPERIENCE

Lignende værker

• Low-dose nivolumab and lenalidomide in relapsed/refractory Hodgkin lymphoma: a single-arm phase 2 trial
  af: Anu Korula, et al.
  Udgivet: (2025-12-01)
• Long term outcomes of allogeneic hematopoietic stem cell transplantation in children with X-linked adrenoleukodystrophies
  af: R.M. Venkatachalam, et al.
  Udgivet: (2022-01-01)
• FLUDARABINE-BASED LOW-INTENSITY CONDITIONING FOR FANCONI ANEMIA IS ASSOCIATED WITH GOOD OUTCOMES IN APLASTIC ANEMIA BUT NOT IN MDS - A SINGLE-CENTER EXPERIENCE
  af: Biju George, et al.
  Udgivet: (2023-06-01)
• Reevaluating Patient Eligibility for Inotuzumab Ozogamicin Based on CD22 Expression: Is Dim Expression Sufficient?
  af: Warren Fingrut, et al.
  Udgivet: (2020-12-01)
• Assessment of clinical immunogenicity of inotuzumab ozogamicin in patients with non-Hodgkin lymphoma and acute lymphoblastic leukemia
  af: Darshana Jani, et al.
  Udgivet: (2018-02-01)